METHODS OF TREATING NEUROLOGICAL AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION

1 . A method of treating a disorder selected from the group consisting of obesity, sexual dysfunction, neuropathic pain, attention deficit disorder, attention deficit hyperactivity disorder, and Parkinson's disease, comprising administering to a patient in need thereof a therapeutically effective amount of a deuterium-enriched compound of Formula I having an optical purity of at least 75% enantiomeric excess to treat the disorder, wherein Formula I is represented by:

or a pharmaceutically acceptable salt thereof, wherein:

A 1 , A 2 , A 3 , and A 4 are independently —C(R 6 )(R 7 )(R 8 );

R 1 , R 2 , R 3 , R 4 , and R 5 are independently H or D;

R 6 , R 7 , and R 8 each represent independently for each occurrence H or D; and

Z is H or D, provided that the abundance of deuterium in Z is at least 30%.

2 . The method of claim 1 , wherein the disorder is obesity.

3 . The method of claim 1 , wherein the disorder is sexual dysfunction.

4 . The method of claim 1 , wherein the disorder is female sexual dysfunction.

5 . The method of claim 1 , wherein the disorder is neuropathic pain.

6 . The method of claim 5 , wherein the neuropathic pain is a postherpetic neuralgia, a trigeminal neuralgia, phantom limb pain, pain associated with diabetic neuropathy, or pain associated with carpal tunnel syndrome.

7 . The method of claim 1 , wherein the disorder is attention deficit hyperactivity disorder.

8 - 15 . (canceled)

16 . The method claim 1 , wherein R 1 , R 2 , R 3 , R 4 , and R 5 are H.

17 . The method claim 1 , wherein

A 1 , A 2 , A 3 , and A 4 are —CH 3 .

18 . The method claim 1 , wherein the compound is a compound of Formula I-A having an optical purity of at least 75% enantiomeric excess, wherein Formula I-A is represented by:

or a pharmaceutically acceptable salt thereof, wherein Z is H or D, provided that the abundance of deuterium in Z is at least 30%.

19 . The method of claim 1 . wherein the abundance of deuterium in Z is at least 60%.

20 . The method of claim 1 , wherein the abundance of deuterium in Z is at least 75%.

21 . The method of claim 1 , wherein the abundance of deuterium in Z is at least 90%.

22 . The method of claim 1 , wherein the compound has an enantiomeric excess of at least 85%.

23 . The method of claim 1 , wherein the compound has an enantiomeric excess of at least 90%.

24 . The method of claim 1 , wherein the compound has an enantiomeric excess of at least 95%.

25 - 59 . (canceled)